Insights into atherosclerosis using nanotechnology

Current Atherosclerosis Reports

Volumn 12, Issue 3, 2010, Pages 209-215

  Jayagopal, Ashwath ^a   Linton, MacRae F ^b   Fazio, Sergio ^b   Haselton, Frederick R ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Inflammation; Macrophage; Nanotechnology; Quantum dot; Vascular imaging

Indexed keywords

FLUOROCARBON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON OXIDE; POLYGLYCOLIDE; POLYLACTIC ACID; NANOPARTICLE;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; BIOSENSOR; CELL THERAPY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; LIPID COMPOSITION; MACROPHAGE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; REVIEW; THROMBOSIS; ANIMAL; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; HUMAN; MEDICAL RESEARCH; METABOLISM; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; BIOMEDICAL RESEARCH; DIAGNOSTIC IMAGING; ENDOTHELIUM, VASCULAR; HUMANS; MACROPHAGES; NANOPARTICLES; NANOTECHNOLOGY; REPRODUCIBILITY OF RESULTS;

EID: 77953542633     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0106-7     Document Type: Review

References (50)

1. Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al.: Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007, 104:961-966. This work describes the evaluation of immunomicelles targeting MSR with high signal-to-background ratios. These approaches may enable noninvasive quantification of macrophage density in vivo for evaluation of lesion severity.
3. Boyle JJ: Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005, 3:63-68.
4. Wagner S, Breyholz HJ, Faust A, et al.: Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr Med Chem 2006, 13:2819-2838.
5. Winter PM, Neubauer AM, Caruthers SD, et al.: Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2103-2109.
6. Muro S, Koval M, Muzykantov V: Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol 2004, 2:281-299.
7. Schellenberger E, Rudloff F, Warmuth C, et al.: Protease-specific nanosensors for magnetic resonance imaging. Bioconjug Chem 2008, 19:2440-2445.
8. Farokhzad OC, Langer R: Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006, 58:1456-1459.
9. Mulder WJ, Cormode DP, Hak S, et al.: Multimodality nanotracers for cardiovascular applications. Nat Clin Pract Cardiovasc Med 2008, 5(Suppl 2):S103-111.
10. Wickline SA, Neubauer AM, Winter P, et al.: Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 2006, 26:435-441.
11. Kelly KA, Allport JR, Tsourkas A, et al.: Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005, 96:327-336.
12. Anderson DR, Tsutsui JM, Xie F, et al.: The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque. Cardiovasc Res 2007, 73:597-606.
13. Jayagopal A, Russ PK, Haselton FR: Surface engineering of quantum dots for in vivo vascular imaging. Bioconjug Chem 2007, 18:1424-1433.
14. Jayagopal A, Su YR, Blakemore JL, et al.: Quantum dot mediated imaging of atherosclerosis. Nanotechnology 2009, 20:165-172.
15. Cormode DP, Skajaa T, Fayad ZA, Mulder WJ: Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol 2009, 29:992-1000.
16. Jaffer FA, Libby P, Weissleder R: Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol 2006, 47:1328-1338.
17. Zhang N, Chittasupho C, Duangrat C, et al.: PLGA nanoparticle- peptide conjugate effectively targets intercellular celladhesion molecule-1. Bioconjug Chem 2008, 19:145-152.
18. Liang B, He ML, Xiao ZP, et al.: Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-targeted gene delivery. Biochem Biophys Res Commun 2008, 367:874-880.
19. Srinivasan R, Marchant RE, Gupta AS: In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J Biomed Mater Res A 2009 (in press)
20. Muro S, Muzykantov VR: Targeting of antioxidant and antithrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des 2005, 11:2383-2401.
21. Wickline SA, Neubauer AM, Winter PM, et al.: Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007, 25:667-680.
22. Libby P, Aikawa M, Jain MK: Vascular endothelium and atherosclerosis. Handb Exp Pharmacol 2006 176(Pt 2):285-306.
23. Dong ZM, Chapman SM, Brown AA, et al.: The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998, 102:145-152.
24. Banquy X, Leclair G, Rabanel JM, et al.: Selectins ligand decorated drug carriers for activated endothelial cell targeting. Bioconjug Chem 2008, 19:2030-2039.
25. Cybulsky MI, Iiyama K, Li H, et al.: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107:1255-1262.
26. Nahrendorf M, Jaffer FA, Kelly KA, et al.: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114:1504-1511.
27. Cormode DP, Skajaa T, van Schooneveld MM, et al.: Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett 2008, 8:3715-3723.
28. Feig JE, Shamir R, Fisher EA: Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 2008, 9:196-203.
29. Chen W, Vucic E, Leupold E, et al.: Incorporation of an apoEderived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 2008, 3:233-242.
30. Cormode DP, Briley-Saebo KC, Mulder WJ, et al.: An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008, 4:1437-1444.
31. Raynal I, Prigent P, Peyramaure S, et al.: Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004, 39:56-63.
32. Boyle JJ, Harrington HA, Piper E, et al.: Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 2009, 174:1097-1108.
33. Sirol M, Itskovich VV, Mani V, et al.: Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 2004, 109:2890-2896.
34. Johnson LL, Schofield L, Donahay T, et al.: 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J Nucl Med 2005, 46:1186-1193.
35. Smith BR, Heverhagen J, Knopp M, et al.: Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). Biomed Microdevices 2007, 9:719-727.
36. Faust A, Wagner S, Law MP, et al.: The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5- [1-(2- methoxymethylpyrrolidinyl)s ulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Imaging 2007, 51:67-73.
37. Lanza GM, Winter PM, Caruthers SD, et al.: Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomed 2006, 1:321-329.
38. Matter CM, Schuler PK, Alessi P, et al.: Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res 2004, 95:1225-1233.
39. Megens RT, Oude Egbrink MG, Cleutjens JP, et al.: Imaging collagen in intact viable healthy and atherosclerotic arteries using fluorescently labeled CNA35 and two-photon laser scanning microscopy. Mol Imaging 2007, 6:247-260.
40. Lancelot E, Amirbekian V, Brigger I, et al.: Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol 2008, 28:425-432.
41. Winter PM, Caruthers SD, Yu X, Song et al.: Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 2003, 50:411-416.
42. Sirol M, Fuster V, Badimon JJ, et al.: Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005, 112:1594-1600. (Pubitemid 41324521)
43. Caves JM, Chaikof EL: The evolving impact of microfabrication and nanotechnology on stent design. J Vasc Surg 2006, 44:1363-1368.
44. Polyak B, Fishbein I, Chorny M, et al.: High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A 2008, 105:698-703. This work describes a promising nanomedicineguided approach for improving stent-based clinical outcomes.
45. Kubo M, Egashira K, Inoue T, et al.: Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler Thromb Vasc Biol 2009, 29:796-801.
46. Harris TJ, von Maltzahn G, Derfus AM, Ruoslahti E, Bhatia SN: Proteolytic actuation of nanoparticle self-assembly. Angew Chem Int Ed Engl 2006, 45:3161-3165.
47. Harris TJ, von Maltzahn G, Lord ME, et al.: Protease-triggered unveiling of bioactive nanoparticles. Small 2008, 4:1307-1312. This work investigates the concept of plaque-triggered nanoscale imaging and therapeutic devices for next-generation clinical approaches.
48. Mayilo S, Kloster MA, Wunderlich M, et al.: Long-range fluorescence quenching by gold nanoparticles in a sandwich immunoassay for cardiac troponin T. Nano Lett 2009 (in press).
49. Wildgruber M, Lee H, Chudnovskiy A, et al.: Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. PLoS One 2009, 4:e5663.
50. Su YR, Blakemore JL, Zhang Y, et al.: Lentiviral transduction of apoAI into hematopoietic progenitor cells and macrophages: applications to cell therapy of atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:1439-1446.